US · Healthcare · Medical Care Facilities
EPS came in at 1.55 against a street estimate of 1.48 — a beat of 4.7%.
Analysts rate Encompass Health Corp a strong buy (12 buy, 0 hold, 0 sell out of 12) with an average price target of $148.17.
CONFIDENT EHC raised FY26 guidance on strong Q2: 9.6% revenue growth, 10.7% adjusted EPS growth. Nursing turnover at 12-year low; acuity mix shifting toward higher-margin stroke/brain injury. North Carolina CON repeal opens major greenfield opportunity. Q2 2026 North Carolina CON repeal is multi-year catalyst; 15-market opportunity could push annual de novo target to high end of 6–10 range starting 2029. Florida and new states demonstrate consistent de novo execution and rapid occupancy ramps. Analysts pressed on acuity sustainability (management cautious on multiyear commitment), North Carolina upside vs. de novo caps (likely to push to high end but not above 6–10 range), and labor inflation offsets (diminishing returns on premium labor; career ladder wages embed modest SWB upside for 2–3 more years). 2026-08-06…
Full summary in the app.
| Fund | Stake |
|---|---|
| BlackRock Inc | 10.92% |
| Vanguard Portfolio Management, LLC | 5.03% |
| T. Rowe Price Associates, Inc. | 4.66% |
| Vanguard Capital Management, LLC | 4.53% |
| Amvescap Plc. | 3.43% |
| Wellington Management Company LLP | 3.32% |
| T. Rowe Price Investment Management,Inc. | 3.27% |
| State Street Corp | 3.19% |
| Document | Date |
|---|---|
| Company announcement · Q3 2026 ENCOMPASS HEALTH CORPORATION – FORM 8-K SUMMARY HEADLINE NUMBERS • Company issued $100 million in aggregate principal amount of 5.875% Senior Notes | 2026-08-13 |
| Quarterly report · Q2 2026 ENCOMPASS HEALTH CORPORATION – Q2 2026 10-Q SUMMARY --- HEADLINE NUMBERS • Net Operating Revenues (Q2 2026): $1,597.4 million vs. $1,457.7 million | 2026-08-07 |
| Results announced · Q3 2026 ENCOMPASS HEALTH Q2 2026 EARNINGS SUMMARY HEADLINE NUMBERS • Net operating revenue Q2 2026: $1,597.4 million, up 9.6% from $1,457.7 million in Q2 20 | 2026-08-05 |
| Material agreement · Q2 2026 ENCOMPASS HEALTH CORPORATION - FORM 8-K SUMMARY HEADLINE NUMBERS • Issued $500 million in aggregate principal amount of 5.875% Senior Notes due June | 2026-06-01 |
| Material agreement · Q2 2026 ENCOMPASS HEALTH CORPORATION – FORM 8-K SUMMARY HEADLINE NUMBERS • Company issuing $500 million in aggregate principal amount of 5.875% senior notes | 2026-05-15 |
| Quarterly report · Q1 2026 ENCOMPASS HEALTH CORPORATION – Q1 2026 10-Q SUMMARY HEADLINE NUMBERS • Net operating revenues: $1,586.6 million (Q1 2026) vs. $1,455.4 million (Q1 2 | 2026-05-01 |
| Proxy statement · Q2 2026 ENCOMPASS HEALTH CORPORATION – 2026 PROXY SUMMARY WHAT SHAREHOLDERS ARE VOTING ON • Proposal 1: Election of 10 Directors – Vote FOR each nominee. Pl | 2026-04-07 |
| Annual report FY2025 ENCOMPASS HEALTH CORPORATION – 10-K SUMMARY HEADLINE NUMBERS • Company: Nation's largest owner/operator of inpatient rehabilitation hospitals by pat | 2026-02-26 |
Readable in the app.
| Action | Detail | Date |
|---|---|---|
| Dividend | $0.21 / share ex-date Oct 1, 2026 · pay Oct 15, 2026 | 2026-10-01 |
| Dividend | $0.19 / share ex-date Jul 1, 2026 · pay Jul 15, 2026 | 2026-07-01 |
| Dividend | $0.19 / share ex-date Apr 1, 2026 · pay Apr 15, 2026 | 2026-04-01 |
| Dividend | $0.19 / share ex-date Jan 2, 2026 · pay Jan 15, 2026 | 2026-01-02 |
| Dividend | $0.19 / share ex-date Oct 1, 2025 · pay Oct 15, 2025 | 2025-10-01 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Encompass Health Corp — free to start.
Google PlayApp StoreData updated 2026-09-18.